Biological Psychiatry (journal)

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024
DSM-IV codes, Research, Type D, Biological Psychiatry (journal), FDA, Food, Schizophrenia, Vortioxetine, PAM, Aggression, Annual general meeting, Society, IPR, Safety, Therapy, Patient, MDD, Pharmaceutical industry

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • In October 2023, Neumora announced that Robert Lenz, M.D., Ph.D., had joined Neumora as executive vice president, head of R&D.
  • Cash Position: As of December 31, 2023, Neumora had cash, cash equivalents and marketable securities of $463.8 million.
  • R&D Expense: Research and development expenses for the fourth quarter of 2023 were $38.9 million, as compared to $23.5 million for the same period in 2022.
  • Net Loss: The Company reported a net loss of $108.7 million for the fourth quarter of 2023, as compared to $28.1 million for the same period in 2022.

Yale School of Medicine Expert to Receive International Mental Health Prize for Ketamine Antidepressant Discovery

Retrieved on: 
Friday, October 6, 2023
National Academy of Medicine, Neuroscience, Multimedia, Food, Doctor of Philosophy, Biological Psychiatry (journal), Yale school, NAM, MD, Translational research, Organization, Krystal, Ketamine, National academy, Psychiatry, FDA, Mental health, Food and Drug Administration, Yale School of Medicine, Depression, Psychology, Patient, Pharmaceutical industry, Yale University, Esketamine, HAVEN

International mental health prize from the National Academy of Medicine goes to a Yale ketamine expert and colleagues.

Key Points: 
  • International mental health prize from the National Academy of Medicine goes to a Yale ketamine expert and colleagues.
  • They are being honored for their discovery of the rapid antidepressant effects of ketamine and the identification of its efficacy for treatment-resistant depression.
  • That discovery led to the development of the antidepressant Esketamine, the first mechanistically novel U.S. Food and Drug Administration (FDA)-approved antidepressant in over 50 years.
  • It is awarded annually to individuals, groups, or organizations that have demonstrated outstanding achievement in improving mental health.

Sahmyook University Researchers Identify Genes Associated with Addiction to Psychostimulant Drugs

Retrieved on: 
Wednesday, August 30, 2023
Arc, COC, Life, Methamphetamine, Brain, Attention, Psychological abuse, Messenger, Assistant, WT, Cocaine, Biological Psychiatry (journal), Nervous system, Sahmyook University, Mouse, Observation, Gene, Addiction, Drug, Pharmaceutical industry, Vaccine, PER2

Per2 is associated with our circadian rhythms, our internal clock which regulates our sleep-wake cycle.

Key Points: 
  • Per2 is associated with our circadian rhythms, our internal clock which regulates our sleep-wake cycle.
  • However, its addictive responses to METH and other psychostimulant drugs like cocaine have not been examined as yet.
  • The researchers first investigated the motivational effect of these drugs and their impact on the locomotor activity of the mice using specialized tests.
  • Using existing data, the researchers could correlate these genes with those that are activated in the region of the brain that responds to drug addiction.

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

Retrieved on: 
Thursday, May 11, 2023
Well, Consensus, Psilocybin, Acceleration, PK, Insurance, GABA, DMT, Society, MCCB, PD, IV, D&O, Benzodiazepine, OTF, VAT, Anorexia nervosa, COMP, PTSD, G&A, Part, Accounting, Anxiety disorder, Patient, Investment, Administration, EEG, Biological Psychiatry (journal), Annual general meeting, Pivotal, CIAS, Entrepreneurship, Oxygen toxicity, Research and development, Research, R, TRD, Safety, Cognitive deficit, Pharmaceutical industry, Palladium, Bank, Surveying, Schizophrenia

The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.

Key Points: 
  • The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.
  • NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates.
  • “This past quarter we made significant progress, including the dosing of the first patient with RL-007 in a randomized, placebo-controlled Phase 2 study.
  • In January 2023, Phase 1 results were announced from the study of GRX-917 in healthy volunteers.

InvestmentPitch Media Video Discusses MindBio Therapeutics’ Take at Home LSD-Microdosing Clinical Trial Published in Peer Reviewed Paper in Biological Psychiatry

Retrieved on: 
Wednesday, May 10, 2023
Volunteering, National Alliance, Male, DNA, CSE, Depression, Canadian Securities Exchange, Suicide, Anxiety, Social connection, Research, LSD, Placebo, Government, Creativity, Medicine, National Alliance on Mental Illness, Patient, Mental disorder, EEG, Blood, Biological Psychiatry (journal), Happiness, Therapy, Death, News, Pharmaceutical industry

For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.

Key Points: 
  • For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “MindBio” in the search box.
  • For more information, please visit the company’s website www.MindBioTherapeutics.com , contact Justin Hanka, CEO, at 61 4331 40886 or by email at [email protected] .

Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

Retrieved on: 
Monday, May 1, 2023
Society, Central nervous system, Psychosis, Brilaroxazine, Deficit spending, NMDA, Dopamine, CNS, Locomotion, DSM-IV codes, Patient, Biological Psychiatry (journal), PPI, Medical research, Pharmaceutical industry, Schizophrenia

CUPERTINO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented the foundational preclinical data that supported the initial clinical development of its novel serotonin-dopamine stabilizer brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) in San Diego. The Company also announced acceptance of this data for publication in Medical Research Archives. The SOBP poster and online publication will be available at revivapharma.com/publications.

Key Points: 
  • The Company also announced acceptance of this data for publication in Medical Research Archives.
  • The SOBP poster and online publication will be available at revivapharma.com/publications .
  • “We were pleased to present at SOBP and simultaneously publish in Medical Research Archives these foundational preclinical data highlighting the antipsychotic effects of brilaroxazine on pharmacologic-induced behaviors associated with psychosis and schizophrenia in translational animal models,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva.
  • “Building on the proof-of-concept data that supported the clinical development of brilaroxazine, these data reinforce the favorable clinical profile seen following dopamine and serotonin pathway modulation in our Phase 2 REFRESH trial in schizophrenia.

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

Retrieved on: 
Friday, April 28, 2023
Biological Psychiatry (journal), Poster, Society, EEG, Benzodiazepine, Annual general meeting, Pharmaceutical industry

NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that pharmacodynamic data on GRX-917, a deuterated version of etifoxine, was selected for poster presentation and presented yesterday at the Society for Biological Psychiatry (SOBP) Annual Meeting. The SOBP annual meeting is being held in San Diego from April 27–29.

Key Points: 
  • NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that pharmacodynamic data on GRX-917, a deuterated version of etifoxine, was selected for poster presentation and presented yesterday at the Society for Biological Psychiatry (SOBP) Annual Meeting.
  • The SOBP annual meeting is being held in San Diego from April 27–29.
  • Late Breaking Poster Presentation Details:
    The analyses in the poster presentation are focused on the pharmacodynamic profile of GRX-917 and are based on the biomarker data from the completed Phase 1 study.
  • The poster will be made available on the atai Life Sciences website at https://ir.atai.life/news-events/events.

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

Retrieved on: 
Tuesday, April 25, 2023
CSE, Prefrontal cortex, DRS, DSM-IV codes, LSD, Biological Psychiatry (journal), Mouse, Lysergic acid diethylamide, IND, Conference, Anxiety, Pharmaceutical industry, Neuroscience

Dr. Lewis will present preclinical data showing that BETR-001 promoted active stress-coping behaviours, and reverses depression and anxiety-like behaviours, in chronically stressed and stress-naïve mouse models.

Key Points: 
  • Dr. Lewis will present preclinical data showing that BETR-001 promoted active stress-coping behaviours, and reverses depression and anxiety-like behaviours, in chronically stressed and stress-naïve mouse models.
  • The positive behavioural effects of BETR-001 correlated with improved spine density (increased neuroplasticity) in the prefrontal cortex of these mice.
  • Furthermore, the mechanism of BETR-001-mediated effects were shown to be driven by the serotonin 5-HT2A receptor in these preclinical models.
  • The presentation abstract is published in the May 1, 2023 edition of the journal of Biological Psychiatry .

Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

Retrieved on: 
Thursday, April 20, 2023
Poster, Central nervous system, Society, RP5063, DSM-IV codes, Biological Psychiatry (journal), CNS, Brilaroxazine, Pharmaceutical industry

CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.

Key Points: 
  • CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.
  • Details for the poster presentation can be found below:
    Brilaroxazine (RP5063), a novel serotonin-dopamine stabilizer, displays antipsychotic efficacy in rodents.

BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting

Retrieved on: 
Thursday, April 20, 2023
Society, Dementia, Depression, Biological Psychiatry (journal), Pharmaceutical industry, Patient

CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry , to be held in San Diego, CA April 27-29, 2023.

Key Points: 
  • CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry , to be held in San Diego, CA April 27-29, 2023.
  • Details for the presentation are as follows:
    Effects of NE3107 on Depression and Multimodal Outcomes in a Phase 2, Open-Label Study in Patients with Cognitive Decline Due to Degenerative Dementias